ATE213955T1 - Verminderung des fettgewebes durch verwendung von kollagenase - Google Patents

Verminderung des fettgewebes durch verwendung von kollagenase

Info

Publication number
ATE213955T1
ATE213955T1 AT95309116T AT95309116T ATE213955T1 AT E213955 T1 ATE213955 T1 AT E213955T1 AT 95309116 T AT95309116 T AT 95309116T AT 95309116 T AT95309116 T AT 95309116T AT E213955 T1 ATE213955 T1 AT E213955T1
Authority
AT
Austria
Prior art keywords
collagenase
reduction
fat tissue
tissue
introducing
Prior art date
Application number
AT95309116T
Other languages
English (en)
Inventor
Edwin H Wegman
Burton Bronsther
Erwin T Jacob
Original Assignee
Advance Biofactures Curacao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advance Biofactures Curacao filed Critical Advance Biofactures Curacao
Application granted granted Critical
Publication of ATE213955T1 publication Critical patent/ATE213955T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
AT95309116T 1994-12-15 1995-12-14 Verminderung des fettgewebes durch verwendung von kollagenase ATE213955T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35611294A 1994-12-15 1994-12-15

Publications (1)

Publication Number Publication Date
ATE213955T1 true ATE213955T1 (de) 2002-03-15

Family

ID=23400188

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95309116T ATE213955T1 (de) 1994-12-15 1995-12-14 Verminderung des fettgewebes durch verwendung von kollagenase

Country Status (6)

Country Link
EP (1) EP0721781B1 (de)
AT (1) ATE213955T1 (de)
CA (1) CA2165271C (de)
DE (1) DE69525728T2 (de)
DK (1) DK0721781T3 (de)
ES (1) ES2173158T3 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3352799A (en) * 1997-10-31 1999-08-23 Children's Medical Center Corporation Method for regulating size and growth of vascularized normal tissue

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US5393792A (en) * 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase

Also Published As

Publication number Publication date
EP0721781A2 (de) 1996-07-17
DE69525728D1 (de) 2002-04-11
EP0721781A3 (de) 1997-08-06
DK0721781T3 (da) 2002-07-01
EP0721781B1 (de) 2002-03-06
DE69525728T2 (de) 2002-10-17
CA2165271C (en) 2010-06-29
CA2165271A1 (en) 1996-06-16
ES2173158T3 (es) 2002-10-16

Similar Documents

Publication Publication Date Title
ATE214274T1 (de) Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
TR199701212T1 (xx) �drar� tutamama halinin tedavisi i�in alfa IL- agonistlerinin kullan�lmas�.
NO975747L (no) Peptidylheterocykler for anvendelse ved behandling av trombin-relaterte mangler
EP1042343A4 (de) Vegi, ein inhibitor der angiogenese und des tumorwachstums
FR10C0016I2 (fr) Procedes et compositions s'appliquant au traitement de la glomerulonephrite
DE69719408D1 (de) Verwendung von Strontiumsälze zur Behandlung von Arthrose
DK0792144T3 (da) Rengøringsvæv behandlet med vand-i-lipid emulsion
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
DE68911103D1 (de) Verwendung von Fettsäuren zur Behandlung von myalgischer Enzephalomyelitis.
DE69834560D1 (de) Verwendung von lactobacillus zur verminderung des fibrinogengehalts im blut
DE3780618D1 (de) Verwendung von buspiron zur verbesserung des kurzzeitgedaechtnisses.
DE69205859D1 (de) Verwendung von oberflächenaktiven Mitteln zur Verbesserung des Rückflusses von Venenkathetern.
DE59406374D1 (de) Hydroxamsäuren und hydroxamsäureether sowie ihre verwendung als komplexbildner
ATE142884T1 (de) Verwendung von magnesium-pyridoxal-5'-phosphat- glutaminat zur verhinderung von krankheiten verursacht durch gefässläsionen
ATE90568T1 (de) Verwendung von zink- oder eisenhydroxid zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen.
DE69434777D1 (de) Verwendung von Relaxin zur Herstellung von therapeutischen Mitteln
TR26214A (tr) Baryum veya stronsiyum sulfid'in lavgalanma artiklarinin hazirlanmasi.
DE69206752D1 (de) Verbesserte Ausführungen von Abfallbehandlung durch Oxydation
ATE106736T1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
ATE77560T1 (de) Verwendung von 2-oxo-pyrrolidin-1-acetamid zur bestimmung der glomerulaeren filtrationsrate beim menschen.
DE69528820D1 (de) Verwendung von Zahnpflegemitteln enthaltend bovines Kolostrum
DE69511148D1 (de) Wegwerfwindel mit verbessertem Abschluss an den Beinteilen
DE69525728D1 (de) Verminderung des Fettgewebes durch Verwendung von Kollagenase
ATE101045T1 (de) Verwendung von zink-calciumhydroxid, lecithin und pao zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee